Scottish Investment Bank

Lentitek is a cell and gene therapy company developing gene therapies and gene-modified cell therapies to broaden access to cures. It focuses on increasing the production yields of lentiviral vectors through its platform, using a novel promoter and proprietary production methods. The approach aims to deliver substantially higher yields, potentially reducing manufacturing costs and improving scalability for healthcare providers delivering gene therapies.

uFraction8 specializes in scalable bioprocessing technology for efficient biomass filtration, separation, and dewatering. Its innovative method is applicable to various microbes like microalgae, yeast, and bacteria, offering a harm-free and flocculant-free alternative to traditional centrifuges, filters, and membranes.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Cytomos Limited, established in 2011 and based in Edinburgh, United Kingdom, specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. The company is known for its patented Dielectric Spectroscopy (CDS) technology, which enables label-free cell analysis with single-cell resolution. This innovative approach provides comprehensive insights into bioprocesses, facilitating automated and quantitative assessments crucial for biomedical research. Cytomos' systems are designed to support biopharma and cell therapy applications by offering deep data analysis per cell, thereby enhancing phenotypic drug discovery and stem cell therapy. By leveraging machine learning algorithms, Cytomos provides researchers with the tools necessary to optimize cell-based diagnostics and ensure accurate dosing in therapeutic contexts.

ILC Therapeutics is a biotechnology company developing novel peptide therapeutics to modulate the innate immune system. Its focus includes treating cancer, atopic dermatitis, psoriasis, and more recently, COVID-19.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

EnteroBiotix develops orally available microbial therapeutics derived from human gastrointestinal tract bacteria. Its focus is preventing and treating diseases by restoring gut microbiota balance.

Glox Therapeutics specializes in developing precision antibiotic therapies derived from naturally occurring bacteriocins. Their focus is on targeting and eliminating specific, hard-to-treat gram-negative bacterial pathogens that are resistant to traditional antibiotics. By preserving the patient's microbiome, their approach aims to minimize side effects and provide a more balanced treatment strategy, thereby advancing the field of antimicrobial therapy.

Beta Bugs specializes in insect genetics, developing high-performance Black Soldier Fly breeds for insect farmers. Headquartered at Easter Bush Campus, it collaborates with the Roslin Institute to enhance productivity in the insect protein sector.

Microplate Dx develops innovative diagnostic technology aimed at reducing fatalities caused by drug-resistant infections. The company, spun out from the University of Strathclyde in Glasgow, focuses on creating point-of-care solutions that accurately detect specific infections and enable optimal antibiotic prescribing within an hour.

Cytomos Limited, established in 2011 and based in Edinburgh, United Kingdom, specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. The company is known for its patented Dielectric Spectroscopy (CDS) technology, which enables label-free cell analysis with single-cell resolution. This innovative approach provides comprehensive insights into bioprocesses, facilitating automated and quantitative assessments crucial for biomedical research. Cytomos' systems are designed to support biopharma and cell therapy applications by offering deep data analysis per cell, thereby enhancing phenotypic drug discovery and stem cell therapy. By leveraging machine learning algorithms, Cytomos provides researchers with the tools necessary to optimize cell-based diagnostics and ensure accurate dosing in therapeutic contexts.

Founded in 2016 and spun out from the University of St Andrews, Pneumagen focuses on developing glycan-targeted carbohydrate-binding modules (CBMs) for treating respiratory tract infections and cancer.

Merck is a German multinational chemical and pharmaceutical company founded in Darmstadt in 1668. It operates in three core segments: Life Science, supplying laboratory reagents, consumables and instruments; Electronics, providing specialty materials for semiconductor and display manufacturing; and Healthcare, developing and selling branded pharmaceuticals with notable focus in oncology, multiple sclerosis and fertility. The company serves customers worldwide across Europe, Africa, Asia, Oceania and Latin America. In the United States and Canada, the brand operates under a separate umbrella reflecting its historical separation from Merck & Co., which remains a separate entity outside Europe. Merck engages in global research, development, production and collaboration to bring new technologies and medicines to market.

Cytomos Limited, established in 2011 and based in Edinburgh, United Kingdom, specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. The company is known for its patented Dielectric Spectroscopy (CDS) technology, which enables label-free cell analysis with single-cell resolution. This innovative approach provides comprehensive insights into bioprocesses, facilitating automated and quantitative assessments crucial for biomedical research. Cytomos' systems are designed to support biopharma and cell therapy applications by offering deep data analysis per cell, thereby enhancing phenotypic drug discovery and stem cell therapy. By leveraging machine learning algorithms, Cytomos provides researchers with the tools necessary to optimize cell-based diagnostics and ensure accurate dosing in therapeutic contexts.

BioCaptiva develops innovative liquid biopsy technology devices aimed at diagnosing and monitoring hard-to-detect cancers. Its proprietary platform captures circulating free DNA from blood samples, overcoming current limitations of cancer liquid biopsy testing.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Axol Bioscience Ltd., established in 2012 and based in Little Chesterford, United Kingdom, specializes in human cell culture systems for research purposes. The company produces and supplies various types of human cells derived from induced pluripotent stem cells (iPSCs), such as cardiomyocytes, neural stem cells, and astrocytes, along with primary cells like endothelial cells and fibroblasts. Axol also provides essential media, reagents, and growth factors to maintain these cell cultures. Additionally, they offer custom services including iPSC reprogramming, differentiation, genome editing, and cell sourcing tailored to clients' needs. Their products are distributed globally through strategic partners in various countries across Asia, North America, Europe, and internationally.

Valneva is a vaccine company focused on developing prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully commercialized two vaccines, IXIARO/JESPECT and DUKORAL, and is advancing candidates against Lyme disease, chikungunya virus, and COVID-19.

uFraction8 specializes in scalable bioprocessing technology for efficient biomass filtration, separation, and dewatering. Its innovative method is applicable to various microbes like microalgae, yeast, and bacteria, offering a harm-free and flocculant-free alternative to traditional centrifuges, filters, and membranes.

Founded in 2016 and spun out from the University of St Andrews, Pneumagen focuses on developing glycan-targeted carbohydrate-binding modules (CBMs) for treating respiratory tract infections and cancer.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

EnteroBiotix develops orally available microbial therapeutics derived from human gastrointestinal tract bacteria. Its focus is preventing and treating diseases by restoring gut microbiota balance.

Macomics is an immuno-oncology company focused on developing immunotherapies that modulate macrophages to reprogram the tumor microenvironment and boost the body's immune response against cancer. The company pursues novel, first-in-class therapies designed to overcome macrophage-driven immunosuppression, enabling broader clinical benefits for patients. Based in Edinburgh, United Kingdom, it develops precision medicines that target macrophage biology to enhance anticancer immunity.

ILC Therapeutics is a biotechnology company developing novel peptide therapeutics to modulate the innate immune system. Its focus includes treating cancer, atopic dermatitis, psoriasis, and more recently, COVID-19.

BioCaptiva develops innovative liquid biopsy technology devices aimed at diagnosing and monitoring hard-to-detect cancers. Its proprietary platform captures circulating free DNA from blood samples, overcoming current limitations of cancer liquid biopsy testing.

Founded in 2016 and spun out from the University of St Andrews, Pneumagen focuses on developing glycan-targeted carbohydrate-binding modules (CBMs) for treating respiratory tract infections and cancer.

Macomics is an immuno-oncology company focused on developing immunotherapies that modulate macrophages to reprogram the tumor microenvironment and boost the body's immune response against cancer. The company pursues novel, first-in-class therapies designed to overcome macrophage-driven immunosuppression, enabling broader clinical benefits for patients. Based in Edinburgh, United Kingdom, it develops precision medicines that target macrophage biology to enhance anticancer immunity.

Founded in 2016 and spun out from the University of St Andrews, Pneumagen focuses on developing glycan-targeted carbohydrate-binding modules (CBMs) for treating respiratory tract infections and cancer.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

Founded in 2009, MedAnnex is a UK-based biotechnology company dedicated to developing first-in-class antibody therapies for treating cancers and autoimmune diseases. Its lead product, annexuzlimab, targets annexin-A1 to inhibit cancer cell growth and autoimmune condition development.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

EnteroBiotix develops orally available microbial therapeutics derived from human gastrointestinal tract bacteria. Its focus is preventing and treating diseases by restoring gut microbiota balance.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Synpromics Ltd. is a biotechnology company based in Edinburgh, United Kingdom, founded in 2010. The company specializes in the development and commercialization of synthetic promoters, which are crucial for controlling gene expression and regulation. Synpromics aims to enhance human health by facilitating the creation of safer and more effective cell and gene therapies. Utilizing proprietary genomics and bioinformatics, along with an intelligent data-driven design approach, Synpromics provides a multi-dimensional bioinformatics database that supports product-specific promoter design and selection. This technology empowers biological researchers and developers in the AgBio sector to innovate and improve efficacy and safety in the development of new medicines and bioprocessing applications. As of August 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

EnteroBiotix develops orally available microbial therapeutics derived from human gastrointestinal tract bacteria. Its focus is preventing and treating diseases by restoring gut microbiota balance.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, established in 2006. The company specializes in the development and commercialization of medical devices and pharmaceuticals centered around Lamellasomes, a synthetic substance that imitates the function of extra-alveolar lamellar bodies. Lamellar Biomedical's innovative products target various respiratory diseases, including cystic fibrosis, and conditions such as radiotherapy-induced xerostomia and dry eye disease. The company’s therapeutic platform leverages anti-infective properties to enhance antibiotic efficacy and protect lung tissues, particularly in complex cases like idiopathic pulmonary fibrosis. Additionally, it facilitates the intracellular delivery of genetic material for pulmonary disease treatment, aiming to provide transformative therapies for severe respiratory conditions. Lamellar Biomedical was previously known as Macrocom (964) Limited before adopting its current name in February 2007.

Synpromics Ltd. is a biotechnology company based in Edinburgh, United Kingdom, founded in 2010. The company specializes in the development and commercialization of synthetic promoters, which are crucial for controlling gene expression and regulation. Synpromics aims to enhance human health by facilitating the creation of safer and more effective cell and gene therapies. Utilizing proprietary genomics and bioinformatics, along with an intelligent data-driven design approach, Synpromics provides a multi-dimensional bioinformatics database that supports product-specific promoter design and selection. This technology empowers biological researchers and developers in the AgBio sector to innovate and improve efficacy and safety in the development of new medicines and bioprocessing applications. As of August 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

Caldan Therapeutics is a spinout from the University of Glasgow and the University of Southern Denmark focused on developing therapeutics that modulate free fatty acid receptors to address metabolic diseases, including Type 2 Diabetes, with potential applications in non-alcoholic steatohepatitis and inflammatory conditions. Building on a long-term collaboration between leading researchers, the company seeks to target multiple aspects of diabetes pathology, such as insulin secretion, insulin sensitivity, and islet cell protection, while aiming to reduce inflammatory activity in muscle, liver, and adipose tissue. The approach centers on delivering glucose-lowering effects by modulating receptor pathways implicated in diabetes and related inflammatory diseases.

Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, that specializes in the development and supply of tuneable peptide hydrogels. Founded in 2012, the company focuses on creating hydrogels specifically designed for cell culture applications, including cell-based toxicity screening, cancer research, and the reduction of animal testing. These hydrogels mimic the chemical and physical properties of natural tissues, allowing researchers to study and manipulate cells within a realistic three-dimensional environment. Biogelx's patented products offer significant advantages for academic institutions, medical researchers, and pharmaceutical companies, providing a viable alternative to existing 3D cell culture solutions. The company's innovative approach aims to facilitate advancements in fundamental cell research and has potential applications in cell therapy and regenerative medicine. Biogelx's hydrogels are currently marketed in the United States, Europe, and Asia.

Clyde Biosciences is a developer of cardiac cell analysis solutions that provide human-relevant data to de-risk drug development. The company creates cell-based assays and analytics to reveal how drug compounds affect heart cells, enabling assessment of efficacy and potential cardiotoxicity in early research. Its offerings include cellOPTIQ, an optical action potential assay that measures drug effects on human cardiomyocytes, and XTENDSR, which quantifies drug-induced changes in cardiac sarcoplasmic reticulum function. By translating cellular responses into functional cardiomyocyte data, Clyde Biosciences supports pharmaceutical and biotechnology companies in identifying safety risks earlier and guiding molecule selection. Headquartered in Glasgow, United Kingdom, the company serves clients internationally and focuses on delivering human-relevant, mechanistic insights to improve the safety profile of new medicines.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

Relitect Limited is a technology company based in Motherwell, United Kingdom, focused on developing innovative diagnostic solutions for the life sciences industry. Founded in 2014, Relitect specializes in a novel assay platform that enables label-free electrochemical detection of binding events. This proprietary technology allows for the highly sensitive analysis of proteins, small molecules, and nucleic acids, making it suitable for clinical diagnostics and research applications. By utilizing small sample volumes and a multiplexed format, Relitect's technology minimizes sample interference and eliminates the potential for cross-talk between labeled reagents, enhancing the accuracy of biomarker detection.

DestiNA Genomics Ltd. is a molecular diagnostic company based in Edinburgh, United Kingdom, and was incorporated in 2010 as a spin-out from the University of Edinburgh. The company specializes in a novel chemical-based system for the detection of nucleic acids and single nucleotide polymorphisms, distinguishing itself from existing enzymatic methods. DestiNA Genomics offers a range of reagents and probes for detecting nucleic acids and mutations, as well as probe sets and assays aimed at drug development and profiling. Its technology is particularly effective for direct detection of micro-RNAs and is being integrated into various detection platforms, including colorimetric, fluorescent, and electrochemical systems. Additionally, DestiNA has established a subsidiary in Spain, DestiNA Genomica SL, to exploit its technology in collaboration with local partners. The company is committed to advancing diagnostic capabilities in areas such as cancer biomarkers, inherited diseases, and infectious diseases.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

Synpromics Ltd. is a biotechnology company based in Edinburgh, United Kingdom, founded in 2010. The company specializes in the development and commercialization of synthetic promoters, which are crucial for controlling gene expression and regulation. Synpromics aims to enhance human health by facilitating the creation of safer and more effective cell and gene therapies. Utilizing proprietary genomics and bioinformatics, along with an intelligent data-driven design approach, Synpromics provides a multi-dimensional bioinformatics database that supports product-specific promoter design and selection. This technology empowers biological researchers and developers in the AgBio sector to innovate and improve efficacy and safety in the development of new medicines and bioprocessing applications. As of August 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, focusing on the ubiquitin and ubiquitin-like signaling systems. The company provides protein degradation-focused drug discovery services and designs novel deubiquitylase (DUB) enzyme inhibitors as potential therapeutics for addressing unmet medical needs. Ubiquigent collaborates with both academic and pharmaceutical researchers, supporting fundamental scientific discovery and the exploration of innovative drug candidates targeting DUBs. Its hybrid business model emphasizes the generation of intellectual property while maintaining an internal pipeline of drug discovery programs aimed at optimizing compounds for critical therapeutic areas.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

Fixed Phage was founded with the aim of developing new products for various industries from our platform technology. Each of our core technologies is comprehensively described and protected by our IP portfolio. We work at our custom designed laboratory and support infrastructure facilities located at the prestigious West of Scotland Science Park. Our in-house abilities include all work required to identify, manufacture and work with bacteriophage. Fixed Phage continually invests in innovation and our team presents at conferences and exhibitions around the world. To learn about whether we will be presenting near you, please follow us on social media.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, established in 2006. The company specializes in the development and commercialization of medical devices and pharmaceuticals centered around Lamellasomes, a synthetic substance that imitates the function of extra-alveolar lamellar bodies. Lamellar Biomedical's innovative products target various respiratory diseases, including cystic fibrosis, and conditions such as radiotherapy-induced xerostomia and dry eye disease. The company’s therapeutic platform leverages anti-infective properties to enhance antibiotic efficacy and protect lung tissues, particularly in complex cases like idiopathic pulmonary fibrosis. Additionally, it facilitates the intracellular delivery of genetic material for pulmonary disease treatment, aiming to provide transformative therapies for severe respiratory conditions. Lamellar Biomedical was previously known as Macrocom (964) Limited before adopting its current name in February 2007.

Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, that specializes in the development and supply of tuneable peptide hydrogels. Founded in 2012, the company focuses on creating hydrogels specifically designed for cell culture applications, including cell-based toxicity screening, cancer research, and the reduction of animal testing. These hydrogels mimic the chemical and physical properties of natural tissues, allowing researchers to study and manipulate cells within a realistic three-dimensional environment. Biogelx's patented products offer significant advantages for academic institutions, medical researchers, and pharmaceutical companies, providing a viable alternative to existing 3D cell culture solutions. The company's innovative approach aims to facilitate advancements in fundamental cell research and has potential applications in cell therapy and regenerative medicine. Biogelx's hydrogels are currently marketed in the United States, Europe, and Asia.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

TPP is a UK-based preclinical-stage drug development company focused on nervous system disorders, immunology, and oncology. They in-license and develop intellectual properties obtained from research institutions, and the resultant products are either distributed via spin-outs or through licensing to the biotech/pharmaceutical sector.

Actual Analytics is a provider of behavior analysis solutions for scientific studies, offering automated video-based tools to monitor laboratory animals. Its products include ActualTrack, which automatically tracks movement of animals such as rodents, drosophila, and zebrafish, and Actual Home Cage Analysis, a non-invasive data collection and automated behavior analysis tool for group-housed rodents. The company serves pharmaceutical and academic research markets, delivering continuous monitoring and detailed locomotor and behavioral outputs to accelerate disease research, improve reproducibility, and reduce manual effort in preclinical studies. It operates through distributors in the United States, Spain, Taiwan, China, and Germany and is headquartered in Edinburgh, United Kingdom. Actual Analytics was founded in 2009.

Syntropharma Limited is an emerging pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the development and distribution of pharmaceutical products, particularly focusing on skin patches that deliver proven medicines for various diseases, including neurological disorders such as Alzheimer's disease and depression. By reformulating commercially successful generic compounds into transdermal applications, Syntropharma aims to enhance their clinical profiles. The company is committed to creating a pipeline of innovative transdermal products protected by strong intellectual property, which it plans to out-license to pharmaceutical partners for broader market reach.

Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.

Big DNA Ltd was set up in 2007 by Dr John March, as a spin out company from the Moredun Research Institute at Edinburgh University, to further develop and commercialise new vaccination technologies. Based at Roslin BioCentre, the company currently employs 7 people.

Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.

CXR Biosciences Limited specializes in preclinical services focused on investigative and mechanistic toxicology, exploratory toxicology, and pharmacokinetics/toxicokinetics. The company evaluates hazards and risks associated with compounds, provides solutions for chemical design and candidate selection, and generates essential metabolic profiling data. CXR Biosciences employs advanced technologies, including in vivo and in vitro methods, genomics, microarrays, and mechanistic assays, to support its clients in ensuring compound safety and optimizing drug development processes. The company serves a diverse clientele, including pharmaceutical, agrochemical, industrial, and biotechnology sectors, along with academic institutions. Established in 2000 and based in Dundee, United Kingdom, CXR Biosciences has developed strong collaborations with over sixty customers and partners to enhance drug development and chemical safety assessment practices.

Big DNA Ltd was set up in 2007 by Dr John March, as a spin out company from the Moredun Research Institute at Edinburgh University, to further develop and commercialise new vaccination technologies. Based at Roslin BioCentre, the company currently employs 7 people.

Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

DC Biosciences Ltd is a biotechnology company based in Dundee, United Kingdom, focused on providing innovative proteomics services and molecular biology solutions to pharmaceutical and biotech firms. Established in 2006 and rebranded from Dundee Cell Products Ltd in 2016, the company specializes in quantitative proteomics technologies that facilitate various preclinical activities in drug discovery. Its offerings include stable isotope labeling with amino acids in cell culture reagents, such as SILAC cell culture media and dialyzed sera, alongside click chemistry reagents. These products support crucial processes such as biomarker discovery and validation, as well as drug re-profiling and repositioning, enabling faster and safer drug development.

Syntropharma Limited is an emerging pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the development and distribution of pharmaceutical products, particularly focusing on skin patches that deliver proven medicines for various diseases, including neurological disorders such as Alzheimer's disease and depression. By reformulating commercially successful generic compounds into transdermal applications, Syntropharma aims to enhance their clinical profiles. The company is committed to creating a pipeline of innovative transdermal products protected by strong intellectual property, which it plans to out-license to pharmaceutical partners for broader market reach.

Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.